Scarica l'app Stockscreener
2.01
1.47%
-0.03
Pre-mercato:
1.70
-0.31
-15.42%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$2.04
Aprire:
$2.06
Volume 24 ore:
838.18K
Relative Volume:
0.45
Capitalizzazione di mercato:
$242.95M
Reddito:
$257.24M
Utile/perdita netta:
$-237.89M
Rapporto P/E:
-0.7731
EPS:
-2.6
Flusso di cassa netto:
$-175.17M
1 W Prestazione:
-3.83%
1M Prestazione:
+21.82%
6M Prestazione:
+119.46%
1 anno Prestazione:
+79.46%
Intervallo 1D:
$1.975
$2.07
Intervallo di 1 settimana:
$1.945
$2.20
Portata 52W:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
2.01 | 246.58M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Oppenheimer | Outperform |
| 2025-09-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com South Africa
Coherus Prices $50.1 Mln Public Offering; Stock Plunges - Nasdaq
Coherus Oncology (CHRS) Launches $50.1M Public Offering - GuruFocus
Coherus Oncology prices stock offering to raise $50.1M - MSN
Coherus Oncology Prices Public Offering at $1.75 per Share - Intellectia AI
Cancer-drug firm Coherus to raise $50M for LOQTORZI, clinical development - Stock Titan
Coherus Oncology announces pricing of public offering of common stock - marketscreener.com
Coherus Oncology Announces Pricing Of Public Offering Of Common Stock - TradingView
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Coherus Oncology announces proposed public offering of common stock - MSN
Coherus Oncology tumbles on planned equity offering - TradingView
Coherus BioSciences (CHRS) Announces Public Stock Offering - GuruFocus
Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Coherus plans stock sale to fund LOQTORZI commercialization - Stock Titan
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology Enters Clinical Supply Agreement with Johnson & Johnson for Combination Cancer Therapy Study - Global Legal Chronicle
Coherus Oncology announces deal with J&J - The Pharma Letter
Johnson & Johnson (JNJ) Partners with Coherus (CHRS) for Cancer Therapy Trial - GuruFocus
Coherus Oncology Inc announces agreement with JanssenSEC filing - marketscreener.com
Coherus Signs Clinical Supply Deal With Janssen Oncology - TipRanks
Coherus Oncology IncAnnounces Agreement With JanssenSEC Filing - TradingView
Coherus Oncology Announces Clinical Supply Agreement with Janssen - TradingView
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks - Cantech Letter
Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks - Newswire Canada
Coherus Oncology (CHRS) Taps ATM Facility: Strategic Lifeline or Dilution Trade-Off for Its Pipeline? - simplywall.st
Coherus Oncology (CHRS) Is Up 28.7% After ATM Offering And Bullish CoverageWhat's Changed - Yahoo Finance
Coherus Oncology Surges 30% Following Oppenheimer’s Outperform Rating - timothysykes.com
Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential - MSN
Coherus BioSciences Shares Surge on Analyst Initiation and Capital Move - AD HOC NEWS
Coherus Oncology Stock Surges Following Analyst Ratings and Clinical Developments - timothysykes.com
Improved Revenues Required Before Coherus Oncology, Inc. (NASDAQ:CHRS) Stock's 54% Jump Looks Justified - 富途牛牛
Investors Purchase Large Volume of Coherus Oncology Call Options (NASDAQ:CHRS) - Defense World
Coherus Oncology files prospectus to offer up to $64.9 million in stock - Investing.com Nigeria
Coherus Biosciences Updates ATM Equity Offering Program - TipRanks
Coherus Oncology Files Prospectus Supplement for Stock Offering - TradingView
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target - Intellectia AI
Coherus Oncology (CHRS) Set for Major Upside with Promising Canc - GuruFocus
Coherus Oncology a new outperform at Oppenheimer on tagmokitug potential ( - Seeking Alpha
Coherus Oncology Sees Unusually Large Options Volume (NASDAQ:CHRS) - MarketBeat
Coherus Oncology stock soars 35% after Oppenheimer initiates with massive upside - Investing.com Canada
Oppenheimer Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Oppenheimer Initiates Coverage on Coherus BioSciences With Outperform Rating - marketscreener.com
Oppenheimer Initiates Coverage of Coherus Oncology (CHRS) with Outperform Recommendation - Nasdaq
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading - intellectia.ai
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Oppenheimer initiates Coherus Biosciences stock with Outperform rating By Investing.com - Investing.com Canada
Oppenheimer initiates Coherus Biosciences stock with Outperform rating - Investing.com
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference - 富途资讯
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):